P4HB and lung carcinoma: Remarkably, in patients with lung cancer as well as in LA-positive patients with thrombosis history [16] we identified a highly significant increase in the PDI family member, P4HB, in platelets, which also manifest this ER chaperone as a highly purposive antithrombotic drug target.